Published in Emerg Infect Dis on November 01, 2003
Pneumonia: update on diagnosis and management. BMJ (2006) 3.69
Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002. Emerg Infect Dis (2005) 3.54
Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev (2005) 3.27
A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res (2013) 2.59
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Nasal carriage of Staphylococcus aureus and methicillin-resistant S aureus in the United States, 2001-2002. Ann Fam Med (2006) 1.37
Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother (2005) 1.34
Antibiotic utilization for acute respiratory tract infections in U.S. emergency departments. Antimicrob Agents Chemother (2013) 1.28
Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis (2004) 1.25
In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother (2007) 1.20
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.02
Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev (2013) 1.01
An ecological approach to assessing the epidemiology of antimicrobial resistance in animal and human populations. Proc Biol Sci (2011) 0.99
Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection (2016) 0.97
Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg Infect Dis (2007) 0.95
Colonization with antibiotic-susceptible strains protects against methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisition: a nested case-control study. Crit Care (2011) 0.93
Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant Bacteria. Front Microbiol (2016) 0.92
Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in dogs and cats: a case-control study. Vet Res (2010) 0.91
Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis (2006) 0.91
Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis (2005) 0.90
Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission. Antimicrob Agents Chemother (2010) 0.90
Skin and skin structure infections: treatment with newer generation fluoroquinolones. Ther Clin Risk Manag (2007) 0.90
Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.90
Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2011) 0.89
Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci. Eur J Clin Microbiol Infect Dis (2005) 0.88
Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis (2005) 0.88
Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection (2006) 0.88
Patient-associated risk factors for acquisition of methicillin-resistant Staphylococcus aureus in a tertiary care hospital. Infect Control Hosp Epidemiol (2010) 0.87
Acquisition of methicillin-resistant Staphylococcus aureus after living donor liver transplantation: a retrospective cohort study. BMC Infect Dis (2008) 0.86
Patterns and determinants of inappropriate antibiotic use in injection drug users. J Gen Intern Med (2008) 0.83
Confounding by indication affects antimicrobial risk factors for methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisition. Antimicrob Resist Infect Control (2014) 0.83
Staphylococcus aureus nasopharyngeal carriage in rural and urban northern Vietnam. Trans R Soc Trop Med Hyg (2014) 0.83
Methicillin-resistant and -susceptible Staphylococcus aureus infections in dogs. Emerg Infect Dis (2010) 0.81
Ten-year decrease of acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at a single institution: the result of a multifaceted program combining cross-transmission prevention and antimicrobial stewardship. Antimicrob Resist Infect Control (2012) 0.81
[Multiresistant bacteria in ophthalmology]. Ophthalmologe (2010) 0.80
The use of the temporal scan statistic to detect methicillin-resistant Staphylococcus aureus clusters in a community hospital. BMC Infect Dis (2014) 0.79
Identification of potential targets in Staphylococcus aureus N315 using computer aided protein data analysis. Bioinformation (2013) 0.78
Urinary Tract Infections: Leading Initiatives in Selecting Empiric Outpatient Treatment (UTILISE). Can J Hosp Pharm (2014) 0.77
Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains. Int J Microbiol (2014) 0.77
Molecular docking and inhibition studies on the interactions of Bacopa monnieri's potent phytochemicals against pathogenic Staphylococcus aureus. Daru (2015) 0.75
Antibacterial potential of streptomycete strains from Antarctic soils. Biotechnol Biotechnol Equip (2014) 0.75
Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures. Eur J Clin Microbiol Infect Dis (2015) 0.75
Phenotypic and genotypic characterisation of multiple antibiotic-resistant Staphylococcus aureus exposed to subinhibitory levels of oxacillin and levofloxacin. BMC Microbiol (2016) 0.75
Correlation between antibiotic consumption and resistance of bloodstream bacteria in a University Hospital in North Eastern Italy, 2008-2014. Infection (2017) 0.75
Chronological changes in microbial profiles in external and middle ear diseases: a 20-year study in Korea. Eur Arch Otorhinolaryngol (2016) 0.75
Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA (1998) 15.66
An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev (1993) 8.03
Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis (2001) 5.07
Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med (1968) 4.38
Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol (1992) 3.80
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis (2002) 2.99
Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis (2001) 2.94
Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol (2001) 2.62
Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother (2002) 2.16
Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis (2001) 2.15
Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med (1987) 2.00
Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis (2001) 1.92
Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother (1997) 1.71
Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2000) 1.67
Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis (1997) 1.63
Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother (2001) 1.44
Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol (1999) 1.31
Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis (2002) 1.26
Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother (2000) 1.23
Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada. Antimicrob Agents Chemother (1991) 1.22
Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J Hosp Infect (2000) 1.21
Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob Agents Chemother (2000) 1.20
Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother (2001) 1.17
Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis (2003) 1.13
Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med (2000) 1.10
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis (2002) 11.30
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis (2006) 7.20
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med (2005) 7.15
Hospital-acquired infections due to gram-negative bacteria. N Engl J Med (2010) 6.61
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother (2009) 6.33
Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother (2003) 6.26
The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol (2005) 5.86
qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother (2006) 5.50
Infections in patients with diabetes mellitus. N Engl J Med (1999) 5.39
Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents Chemother (2006) 4.96
Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother (2002) 4.83
Diagnosis and management of infective endocarditis and its complications. Circulation (1999) 4.77
Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother (2006) 4.50
Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev (2009) 4.43
Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis (2010) 4.25
Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis (2003) 4.06
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother (2007) 4.03
Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother (2005) 4.03
Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med (1983) 3.97
Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med (2008) 3.88
Assessment and management of foot disease in patients with diabetes. N Engl J Med (1994) 3.83
Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis (2013) 3.78
Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother (2007) 3.74
Plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica. Clin Infect Dis (2006) 3.66
High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother (2007) 3.62
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis (2013) 3.56
Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother (2007) 3.55
Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother (2004) 3.54
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2006) 3.33
Prosthetic valve endocarditis. Analysis of 38 cases. Circulation (1973) 3.29
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect (2011) 3.10
Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother (2006) 3.09
Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med (1999) 3.08
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis (2002) 2.99
Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA (2008) 2.95
First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother (2008) 2.93
The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis (2003) 2.92
Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA (2004) 2.90
Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother (2005) 2.90
Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis (2011) 2.89
Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol (2007) 2.85
Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother (2008) 2.70
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA (1990) 2.61
Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis (2003) 2.60
Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med (1999) 2.56
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis (2001) 2.53
Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis (2005) 2.52
Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis (2004) 2.48
Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis (2003) 2.44
Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother (2008) 2.38
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 2.33
New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother (2009) 2.32
Diagnosis and therapy of Kawasaki disease in children. Circulation (1993) 2.32
Antimicrobial resistance to linezolid. Clin Infect Dis (2004) 2.30
Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis (1994) 2.29
Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains. J Clin Microbiol (1994) 2.23
Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis (2002) 2.18
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis (2005) 2.10
Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA (1995) 2.09
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med (2002) 2.00
Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258. Antimicrob Agents Chemother (2010) 1.97
Case records of the Massachusetts General Hospital. Case 3-2015. A 60-year-old woman with abdominal pain, dyspnea, and diplopia. N Engl J Med (2015) 1.97
Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis (1998) 1.97
Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis (2009) 1.92
Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis (2004) 1.91
High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2005) 1.90
Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol (2006) 1.88
A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med (2011) 1.88
Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis (2004) 1.87
Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med (1996) 1.84
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol (2003) 1.81
Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 1.80
Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis (1991) 1.77
The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol (2005) 1.77
oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother (2009) 1.77
Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother (2002) 1.71
Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother (2007) 1.68
Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob Agents Chemother (2005) 1.67
Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother (2006) 1.66
Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med (1995) 1.64
Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol (2011) 1.64
Adequacy of fellowship training: results of a survey of recently graduated fellows. Clin Infect Dis (2001) 1.63
Late prosthetic valve endocarditis: clinical features influencing therapy. Am J Med (1978) 1.62
Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg (1977) 1.60
Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med (1991) 1.59
Plasmid-pattern analysis for the differentiation of infecting from noninfecting Staphylococcus epidermidis. J Infect Dis (1984) 1.59
Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. N Engl J Med (1990) 1.58
Discontinuation of contact precautions for methicillin-resistant staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. Clin Infect Dis (2013) 1.57
Enhanced identification of postoperative infections among inpatients. Emerg Infect Dis (2004) 1.56
Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am J Med (1985) 1.54
Native valve endocarditis due to coagulase-negative staphylococci. Clinical and microbiologic features. Am J Med (1987) 1.54